Brief: Alligator Bioscience, Aptevo Therapeutics Announce Positive Interim Data Of Dose Escalation Phase Of ALG.APV-527 Phase 1 Study
07/03/2024 15:34
March 7 (Reuters) -
Alligator Bioscience and Aptevo Therapeutics:
* ALLIGATOR BIOSCIENCE: POSITIVE INTERIM DATA OF DOSE
ESCALATION
PHASE OF ALG.APV-527 PHASE 1 STUDY IN SOLID TUMOR CANCERS
EXPRESSING TUMOR ANTIGEN 5T4
* ALLIGATOR BIOSCIENCE AB: INITIAL INTERIM DATA SHOW
FAVORABLE
DRUG EXPOSURE AND CONFIRM ALG.APV-527 BIOLOGICAL ACTIVITY
Further company coverage: APVO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aptevo Therapeutics
See all newsBrief: Aptevo Therapeutics - Enters Amendment No. 6 To Rights Agreement On October 23, 2026 - SEC Filing
U.S. STOCKS ON THE MOVE-Principal Financial Group, NetApp
U.S. STOCKS ON THE MOVE-Genesco, Fervo Energy, Tyson Foods
Aptevo Therapeutics reports early data for blood cancer therapy; shares fall
Aptevo Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary